Physiology or Medicine, 1937).
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. Vitamins and their metabolites are essential for a large number of physiological processes, fulfilling diverse functions as hormones and antioxidants, as regulators of tissue growth and differentiation, in embryonic development and in calcium metabolism, among others 1 . In addition, vitamins have a role in the immune system, which extends to both innate and adaptive immune responses. Although some vitamins, such as vitamins C and E and members of the B complex, can act in a relatively nonspecific manner in the immune system (for example, as antioxidants) [2] [3] [4] , other vitamins, such as vitamins A and D, can influence the immune response in highly specific ways (see Supplementary information S1 (table) ). Here we review the most important effects of vitamins on the immune system, with special emphasis on vitamins A and D, which have received particular attention owing to recent discoveries of their multi-faceted interactions with the immune system. Vitamins A and D are notably distinct from other vitamins in that their respective bioactive metabolites, retinoic acid and 1,25-dihydroxyvitamin D3
(1,25(OH) 2 VD 3 ), have hormone-like properties. Both of these metabolites are synthesized from their vitamin precursors by different tissues and cells in the body and exert their effects on target cells remotely by binding to nuclear-hormone receptors.
Vitamin metabolism in the immune system Vitamin D. Vitamin D 3 (VD 3 ), the most physiologically relevant form of vitamin D, is synthesized in the skin from 7-dehydrocholesterol 5 , a process which depends on sunlight, specifically ultraviolet B radiation (wavelengths of 270-300 nm). Alternatively, it can be acquired in the diet or in vitamin supplements 5 (FIG. 1a) . VD 3 is then converted in the liver to 25-dihydroxyvitamin D 3 (25(OH)VD 3 ), which is the main circulating form of VD 3 . Finally, 25(OH)VD 3 is metabolized in the kidneys to 1,25(OH) 2 VD 3 , the most physiologically active VD 3 metabolite 5 . In addition to being processed in the liver and the kidneys, VD 3 can also be metabolized by cells of the immune system 5, 6 (FIG. 1a) . In this way, 1,25(OH) 2 VD 3 is concentrated locally in those lymphoid microenvironments that contain physiologically high concentrations of VD 3 , thereby increasing its specific action and also limiting potentially undesirable systemic effects, such as hypercalcaemia and increased bone resorption 7 . Activated T cells (and probably also B cells) can only perform the final step of converting 25(OH)VD 3 to 1,25(OH) 2 VD 3 (reFs 6, 8) . However, macrophages and some dendritic cells (DCs), such as monocyte-derived DCs and dermal DCs, express the two sets of enzymes needed to convert VD 3 into 1,25(OH) 2 VD 3 (reFs 6,7,9). (VD 3 ) is acquired in the diet or synthesized in the skin and hydroxylated in the liver to 25(OH)VD 3 , the main circulating form. 25(OH)VD 3 is then hydroxylated in the kidneys by the cytochrome P450 protein CYP27B1 to become 1,25(OH) 2 VD 3 , the physiologically most active metabolite, which then reaches the blood where it has multiple systemic effects. Cells of the immune system, including macrophages, dendritic cells (DCs), T and B cells express the enzymes CYP27A1 and/or CYP27B1, and therefore can also hydroxylate 25(OH)VD 3 to 1,25(OH) 2 VD 3 . 1,25(OH) 2 VD 3 acts on immune cells in an autocrine or paracrine manner by binding to the vitamin D receptor (VDR). 24-hydroxylase (CYP24A1) catabolizes 1,25(OH) 2 VD 3 to its inactive metabolite, calcitroic acid, which is excreted in the bile. b | Vitamin A (also known as retinol) is obtained from the diet and transported in the blood as a complex with retinol-binding protein (RBP) and transthyretin (TTR). In the liver, retinol is esterified to retinyl esters and stored in stellate cells. In other tissues, including gut-associated immune cells, retinol is oxidized to retinal by alcohol dehydrogenases (ADHs) or short chain dehydrogenase/reductases (SDRs). Retinal is then oxidized to all-trans-retinoic acid in an irreversible reaction that is catalysed by retinal dehydrogenases (RALDHs). Retinoic acid acts on immune cells by binding to the retinoic acid receptor (RAR). Retinoic acid is catabolized in the liver and in other tissues by the enzyme CYP26 and its metabolites are eliminated in the bile and urine. c | Retinoid X receptors (RXRs) can form RXR-RAR ( receptor for all-trans-and 9-cis-retinoic acid), RXR-PPARβ (peroxisome-proliferator-activated receptor β)(receptor for fatty acids), RXR-RXR (receptor for 9-cis-retinoic acid), or RXR-VDR (receptor for 1,25(OH) 2 VD 3 ) complexes. The ratio between cellular retinoic acid-binding proteins (CRABPs) and fatty acid-binding protein 5 (FABP5) might determine whether retinoic acid signals through RAR-RXR or PPARβ-RXR, leading to different functional outcomes. RARE, retinoic acid response element; VDRE, VD response element. Intestinal epithelial cells (IeCs) . A tight monolayer of cells covering the luminal surface of the intestine. They are specialized in the absorption of nutrients and also serve as a mechanical and immunological barrier with the external environment (the intestinal lumen).
Peyer's patches
Groups of lymphoid nodules present in the small intestine (usually the ileum). They are found massed together on the intestinal wall, opposite the line of attachment of the mesentery. Peyer's patches consist of a dome area, B-cell follicles and interfollicular T-cell areas. Finally, the enzyme 24-hydroxylase, which is most abundant in the kidney and intestine 10 , catabolizes 1,25(OH) 2 VD 3 to its inactive metabolite, calcitroic acid, which is then excreted in the bile.
Mesenteric lymph nodes
Vitamin A. Vitamin A is obtained from the diet either as all-trans-retinol, retinyl esters or β-carotene 11, 12 (FIG. 1b) . All-trans-retinol is esterified to retinyl esters and stored in the liver, mostly in the stellate cells 11, 12 . In the tissues, all-trans-retinol and β-carotene are oxidized to all-trans-retinal by alcohol dehydrogenases or short chain dehydrogenase reductases, which are ubiquitously expressed enzymes 11, 12 . All-trans-retinal is then oxidized to all-trans-retinoic acid through an irreversible reaction catalysed by retinal dehydrogenases (rAlDHs), the expression of which is tightly controlled. A related metabolite of all-trans-retinal, 9-cis-retinoic acid, can be formed either by spontaneous isomerization of alltrans-retinoic acid or through oxidation of 9-cis-retinal by rAlDH 13 . However, 9-cis-retinoic acid has not been shown to be synthesized in vivo 13 . In adult mammals, rAlDH can be found in some gut-associated cells, including intestinal epithelial cells (IECs) 14, 15 and gut-associated DCs, such as DCs from Peyer's patches and mesenteric lymph nodes 15, 16 . Interestingly, DCs from Peyer's patches express rAlDH-1 mrNA and protein, whereas DCs from mesenteric lymph nodes express mrNA encoding rAlDH-2. Although the functional relevance of this differential rAlDH isoform expression is currently unclear, it indicates that there might be more than one pathway or environmental stimulus that renders DCs capable of synthesizing retinoic acid from vitamin A. In addition, IECs also express rAlDH-1 and can metabolize vitamin A to retinoic acid in vitro 14 , which indicates that they are another potential source of retinoic acid in the gut mucosa. The relative contributions and in vivo relevance of these different sources of retinoic acid in the gut are yet to be determined.
Nuclear receptors for vitamin metabolites locally produced 1,25(OH) 2 VD 3 can act on immune cells in an autocrine or paracrine manner. On complexing with 1,25(OH) 2 VD 3 , the nuclear vitamin D receptor (VDr) heterodimerizes with nuclear receptors of the retinoic X receptor (rXr) family -which has three main isoforms: α, β and γ -and binds to VD 3 response elements (VDrEs) in the promoters of VD 3 -responsive genes (FIG. 1c) .
Similarly, retinoic acid exerts its multiple effects by binding to nuclear receptors of the retinoic acid receptor (rAr) family, which also has three main isoforms: α, β and γ. These form rAr-rXr heterodimers, which interact with retinoic acid response elements (rArEs) within the promoters of retinoic acid-responsive genes 11, 12 . rAr proteins are ubiquitously expressed and are also upregulated by retinoic acid 11, 12 . As mentioned above, rXr proteins can also pair with VDr proteins or form rXr-rXr homodimers, which are specific receptors for 9-cis-retinoic acid but not for all-trans retinoic acid (hereafter referred to as retinoic acid) (although 9-cis-retinoic acid can also signal through rAr-rXr heterodimers). In addition, rXr proteins are partners for other nuclear receptors, such as thyroid hormone receptor, peroxisome proliferatoractivated receptor (PPAr) and liver X receptor, among others 17 . Therefore, it is possible that, given their common rXr nuclear binding partners, some ligands, such as 1,25(OH) 2 VD 3 and retinoic acid, might antagonize each other's effects 18 . Notably, retinoic acid can also bind and signal through the PPArβ (also known as PPArδ) nuclear receptor 19 . whether signalling occurs through rAr or PPArβ depends on the ratio of cellular retinoic acid-binding proteins (CrABPs) to fatty acid-binding protein 5 (FABP5), which ultimately determines the partitioning of retinoic acid between the two types of receptors 19 . In this model, a high CrABP:FABP5 ratio promotes rAr signalling by CrABP-mediated 'channelling' of retinoic acid to rAr, which results in growth inhibition and apoptosis in some cell lines, whereas a low ratio favours FABP5-mediated delivery of retinoic acid to PPArβ and survival in the same cells 19 . However, although this is a potentially attractive mechanism for regulating retinoic acid responses, its significance in the immune system is yet to be determined.
Immunomodulatory role of vitamin D
The influence of VD 3 metabolites in the immune system, particularly of 1,25(OH) 2 VD 3 , has been known for more than 20 years 20, 21 . In vitro, 1,25(OH) 2 VD 3 exerts a marked inhibitory effect on adaptive immune cells (FIG. 2) . It inhibits T-cell proliferation 20, 21 , the expression of interleukin-2 (Il-2) [21] [22] [23] and interferon-γ (IFNγ) mrNA and protein in T cells 24, 25 , and CD8 T-cell-mediated cytotoxicity 26 . The decrease in the production of Il-2 and IFNγ by 1,25(OH) 2 VD 3 is partially mediated by binding of the VDr-rXr complex to the VDrE in the promoters of genes encoding Il-2 (reF. 27) and IFNγ (reF. 28 ). The anti-proliferative effect could be explained, at least in part, by the decrease in Il-2 production, as proliferation is partially rescued by adding exogenous Il-2 (reFs 21, 22, 29) . These inhibitory effects of 1,25(OH) 2 VD 3 are most pronounced in the memory T-cell compartment 30 , which is concomitant with the higher expression of VDr in effector and memory T cells compared with naive T cells 31 . Moreover, 1,25(OH) 2 VD 3 enhances nonspecific T-cell suppressor activity, as measured by the ability of 1,25(OH) 2 VD 3 -treated T cells to suppress primary mixed-lymphocyte reactions and cytotoxic T-cell responses 26 . Overall, the net result of 1,25(OH) 2 VD 3 action on T cells is to block the induction of T-helper-1 (T H 1)-cell cytokines, particularly IFNγ, while promoting T H 2-cell responses, an effect mediated both indirectly by decreasing IFNγ production and directly by enhancing Il-4 production 7 . The activity of 1,25(OH) 2 VD 3 on effector T-cell differentiation is further enhanced by its effect on antigen-presenting DCs, in which it suppresses the synthesis of Il-12, a cytokine that promotes T H 1-cell responses 32, 33 . to inhibit Il-6 and Il-23 production 34, 35 , and induces the reciprocal differentiation and/or expansion of forkhead box protein 3 (FOXP3) + regulatory T (T reg ) cells [35] [36] [37] . In addition to its inhibitory effects on T cells, 1,25(OH) 2 VD 3 decreases B-cell proliferation, plasma-cell differentiation and IgG secretion 8, 20 (FIG. 2) . It has been suggested that the effect of 1,25(OH) 2 VD 3 on B cells might be indirectly mediated through the effect it has on antigen-presenting-cell (APC) function and/or T-cell help 38 . Indeed, there are conflicting reports concerning the expression of VDr by B cells 8, 31, 39 , leaving it unclear whether 1,25(OH) 2 42 and has been shown to increase the production of both Il-1 and the bactericidal peptide cathelicidin by monocytes and macrophages 5, 23 . unexpectedly, in spite of the potentially important role of 1,25(OH) 2 VD 3 in maintaining immune homeostasis, VDr-deficient mice have a normal composition of immune-cell populations and reject allogeneic and xenogeneic transplants at the same rate as wild-type mice 43 . However, to carefully dissect the in vivo effects of VD 3 metabolites on the immune response, it will be necessary to study the effect of VD 3 in animal models in which VDr deficiency is restricted to T cells, B cells and myeloid cells. Immunomodulatory role of vitamin A Effects on adaptive immune-cell subsets. Vitamin A metabolites can also affect some aspects of the adaptive immune response (FIG. 3) . retinoic acid enhances cytotoxicity 44 and T-cell proliferation 45 , the latter probably mediated, at least in part, by enhancing Il-2 secretion and signalling in T cells 45 . Consistent with an in vivo role for vitamin A in T-cell function, vitamin Adeficient mice have defects in T H -cell activity 46 . A possible mechanism for this observation is that in the setting of vitamin A deficiency, retinoic acid does not compete with 1,25(OH) 2 VD 3 for their common nuclear binding partner rXr and, therefore, the inhibitory effects of 1,25(OH) 2 VD 3 on T-cell function (including T H -cell activity) are not offset by retinoic acid.
retinoic acid can inhibit B-cell proliferation 47, 48 , although it has also been found to enhance B-cell activation under some conditions 49, 50 . In addition, retinoic acid inhibits B-cell apoptosis. These effects are mediated through binding of vitamin A metabolites to rAr receptors 51 .
Notably, it has been reported that a distinct set of vitamin A metabolites classified as retro-retinoids can also affect general lymphocyte functions such as B-cell proliferation 52 and T-cell activation and proliferation 52 . 14-hydroxy-retroretinol (14Hrr) has a positive effect on proliferation, whereas anhydroretinol blocks B-cell proliferation and induces apoptosis in T cells 53 . retroretinoids do not signal through rAr or rXr and, as 14Hrr and anhydroretinol can antagonize each other's effects, it has been suggested that they might compete for a common, as-yet unknown receptor 53 . retinoic acid can also modulate antigen presentation by exerting direct effects on DC function. For example, retinoic acid increases the expression of matrix metallo proteinases, thereby increasing the migration of tumour-infiltrating DCs to the draining lymph nodes, which have the potential to boost tumour-specific T-cell responses 54 . In addition, in the presence of inflammatory stimuli, such as tumour-necrosis factor (TNF), retinoic acid enhances DC maturation and antigenpresenting capacity, both of which are effects mediated Nature Reviews | Immunology In MALT (including the gut-associated lymphoid tissue; GALT), TGFβ and CD40 ligand (CD40L) are essential for the generation of T-cell-dependent IgA responses, whereas BAFF (B-cell-activating factor) and APRIL (a proliferation-inducing ligand) are important for T-cell-independent IgA responses. APRIL is induced by Toll-like receptor (TLR) signals, commensal flora and thymic stromal lymphopoietin (TSLP). Inducible nitric oxide synthase (iNOS), which is also upregulated by TLR signals and commensal flora, produces nitric oxide (NO), allows proper TGFβ signalling and induces the production of APRIL and BAFF by dendritic cells. Thus, iNOS and NO are essential for both T-cell-dependent and -independent IgA responses. In the GALT, retinoic acid might contribute directly to the differentiation of T-cell-independent (and probably also T-cell-dependent) IgA + ASCs. In addition, retinoic acid might contribute indirectly to T-cell-dependent and -independent IgA responses by inducing iNOS expression.
Gut-associated lymphoid tissue
(GALT). Lymphoid structure associated with the intestinal mucosa, including cryptopatches, isolated lymphoid follicles, Peyer's patches and caecal and colonic patches.
Small intestinal lamina propria
Connective tissue between the intestinal epithelium and the intestinal muscularis mucosae layer, which contains various myeloid and lymphoid cells, including macrophages, dendritic cells, T cells and B cells.
by rXr receptors 55 . However, it should be noted that DCs pre-treated with retinoic acid can apparently store this metabolite 50 , which when released could ultimately act directly on T cells and/or other cells and contribute to the final outcome of an immune response.
Vitamin A metabolites also modulate more specific functional aspects of the immune response, such as the T H 1-T H 2-cell balance and the differentiation of T reg cells and T H 17 cells (FIG. 3a) . Vitamin A deficiency correlates with decreased T H 2-cell responses 56 and, conversely, vitamin A supplementation blocks the production of T H 1-cell cytokines in vitro and in vivo 57, 58 . These effects of vitamin A on T H 1-T H 2-cell differentiation are mediated by retinoic acid. In fact, retinoic acid promotes T H 2-cell differentiation by inducing IL4 gene expression 59 . Moreover, retinoic acid blocks the expression of the T H 1-cell master regulator T-bet and induces T H 2-cellpromoting transcription factors, such as GATA3 (GATAbinding protein 3), macrophage-activating factor (MAF) and signal transducer and activator of transcription 6 (STAT6) 57, 60 . Interestingly, vitamin A supplementation was correlated with an increase in disease severity in a mouse model of asthma, whereas vitamin A deficiency had the opposite effect, which was associated with a decrease in T H 2-cell cytokines 61 . It has been proposed that retinoic acid exerts its T H 2-cell-promoting effect indirectly through the modulation of APCs 62 . However, retinoic acid can also act directly on T cells to induce T H 2-cell differentiation 57, 60 through rAr proteins 57 . Several types of T cells that have dominant immunomodulatory effects have been described. The best characterized are T reg cells that express the transcription factor FOXP3. Although transforming growth factor-β (TGFβ) drives the generation of induced T reg cells in peripheral tissues 63 , it was recently demonstrated by several groups that this process can be significantly enhanced by retinoic acid 64, 65 (FIG. 3a) . In addition, DCs from the gut-associated lymphoid tissue (GAlT) or small intestinal lamina propria also enhance T reg -cell differentiation in a retinoic acid-dependent manner 16, 66 . Notably, one recent study indicated that macrophages and not DCs are responsible for inducing T reg cells in the intestinal lamina propria 67 , and that DCs are mainly involved in the induction of T H 17 cells at this site 67, 68 . The reasons for these seemingly discrepant results are unclear. In addition to inducing FOXP3, retinoic acid also upregulates gut-homing receptors on T reg cells, targeting these cells to the gut mucosa 65, 66 . The relative contribution of in situ-generated gut T reg cells to both oral and peripheral tolerance is yet to be determined. . However, exposure of CD4 + T cells to retinoic acid together with TGFβ and Il-6 negates the T H 17-cell-promoting effect of Il-6 by enhancing the induction of T reg cells and blocking the induction of retinoic-acid-receptor-related orphan receptor-γt (rOrγt), a key transcription factor for T H 17-cell differentiation 64, 71 .
It should be noted that this effect is only observed when retinoic acid is used over a certain threshold concentration 68 . In fact, low concentrations of retinoic acid seem to be necessary for T H 17-cell differentiation 68 . So, retinoic acid has a dual role in maintaining immunological tolerance: it favours the induction of T reg cells and can simultaneously either block or enhance T H 17-cell differentiation, depending on its concentration. . GAlT-and lamina propria-resident DCs also contribute to the generation of IgA + ASCs by a mechanism depending, at least in part, on retinoic acid 68, 76 (FIG. 3b) .
Effects on immunoglobulin isotypes.
The presence of retinoic acid efficiently induces IgA secretion by lipopolysaccharide (lPS)-activated splenocytes 80 or by lPS-stimulated B cells cultured with spleen DCs 68 . However, the presence of retinoic acid during the activation of purified B cells is not sufficient to impart these effects 68, 76 . retinoic acid-induced IgA secretion requires either Il-5 (reFs 76,80) or Il-6 (reFs 75,76), which are known to possess a general adjuvant role in IgA production 73, 81, 82 . In fact, both retinoic acid and Il-6 are required for GAlT-resident DCs to induce optimal IgA production by mouse and human B cells in vitro 75, 76 . Vitamin A-depleted mice have decreased numbers of IgA + ASCs in the small bowel lamina propria 76, 83 , consistent with an in vivo role for retinoic acid in gut mucosal IgA responses. In addition, oral administration of a rAr agonist significantly increases serum IgA levels in rats 84 . Interestingly, exposure to retinoic acid together with Il-6 or Il-5 is not sufficient to induce IgA + ASCs from in vitro-activated naive B cells in the absence of DCs 76 . Therefore, it is likely that DCs provide some necessary B-cell survival and differentiation signals that are not tissue-specific.
It was recently shown that inducible nitric oxide synthase (iNOS; also known as NOS2A) and nitric oxide are crucial for the generation of IgA + ASCs
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. Interestingly, the promoter of the iNOS gene contains a rArE that is directly activated by retinoic acid bound to its nuclear rArα-rXr heterodimeric receptor 85 . Moreover, intraperitoneal administration of either retinoic acid or a rAr agonist enhances lPS-induced iNOS expression in several organs and increases plasma levels of nitrate and nitrite in rats 86 . Therefore, retinoic acid might also indirectly contribute to IgA secretion by inducing iNOS and nitric oxide expression.
Precursors of retinoids in the diet (which include β-carotene and retinyl esters) are absorbed from the gut lumen and can be metabolized to produce retinoic acid in IECs 14 and in DCs that reside near the germinal centres in Peyer's patches 15 . The proximity of Peyer's patches to the gut bacterial flora and to other potential sources of retinoic acid and cytokines, such as IECs, could help to explain the predominance of IgA class-switching that occurs in Peyer's patches compared with mesenteric lymph nodes 87 . Consistent with a role for vitamin A in gut IgA production, rats or mice depleted of vitamin A have decreased levels of total IgA in intestinal lavages and decreased mucosal antigen-specific IgA responses, which correlates with decreased protection against infections and oral bacterial toxins 56, 88, 89 . Furthermore, vitamin A supplementation prevents the decline in IgA levels observed in malnourished mice 58 . In addition to a direct effect on ASCs, it should be considered that vitamin A deficiency could also decrease IgA secretion in the gut by reducing the expression of the polymeric immunoglobulin receptor, leading to a decrease in the secretion of dimeric IgA to the gut lumen 88, 89 . Moreover, although vitamin A-deficient mice have decreased numbers of IgA + ASCs in the small bowel 76, 83 , their serum IgA levels are normal 76 , which indicates that retinoids are not absolutely required for generating IgA + ASCs in other mucosal compartments.
Vitamin metabolites and lymphocyte homing
Although naive lymphocytes migrate mainly through secondary lymphoid organs, effector and memory lymphocytes acquire 'traffic' molecules that endow them with the capacity to migrate to select extralymphoid tissues and to sites of inflammation. Of the extralymphoid compartments, the gastrointestinal mucosa and the skin are the two main body surfaces exposed to environmental antigens and are also the two paradigmatic tissues for which tissue-specific adhesion and chemoattractant receptors (also known as homing receptors) have been characterized in detail. For example, effector and memory lymphocytes migrating to the small bowel require expression of the α 4 β 7 -integrin and CC-chemokine receptor 9 (CCr9), whereas those migrating to the skin rely on the expression of ligands for E-and P-selectin and CCr4 or CCr10 (reF. 73) (FIG. 4a) . It has been demonstrated that the lymphoid microenvironment in which lymphocytes are activated determines the set of homing receptors that they acquire -for example, T cells activated in skin-draining lymph nodes acquire skin-homing receptors whereas those activated in the GAlT acquire gut-homing receptors 90 . In the lymphoid microenvironment, DCs are essential for efficient T-cell activation 91 . Several groups have shown that DCs from Peyer's patches and mesenteric lymph nodes are sufficient to induce the expression of α 4 β 7 -integrin and CCr9 and therefore imprint gut-homing capacity on activated mouse T cells [92] [93] [94] [95] [96] and mouse and human B cells 68, 76 , whereas lymphocytes activated by mouse DCs from peripheral lymph nodes preferentially acquire skin-homing receptors 95, 96 . How do GAlT-resident DCs imprint lymphocytes with a gut-homing phenotype? More than 25 years ago it was shown that rats suffering from both proteincaloric and vitamin A deficiencies exhibited impaired migration of recently activated mesenteric lymphocytes to the small intestinal mucosa 97 . Protein-caloric malnutrition without vitamin A deficiency did not affect lymphocyte migration 97 . Adoptive transfer experiments showed that impaired lymphocyte migration was observed only when donor lymphocytes were from protein-caloric-deficient and vitamin A-deficient rats and not when wild-type cells were transferred to protein-caloric-deficient and vitamin A-deficient recipients 97 . This suggests that vitamin A deficiency mainly affected lymphocyte migratory capacity, but not the target tissues 97 . More recently, it was described that vitamin A-depleted rats had a marked decrease in the number of IgA + ASCs and CD4 + T cells in the ileum 83 . The molecular basis for these observations was recently determined in a study that showed that mice depleted of vitamin A had decreased numbers of effector and memory T cells in the gut mucosa, but not elsewhere 15 . The vitamin A metabolite retinoic acid was sufficient to induce the expression of α 4 β 7 -integrin and CCr9 by activated T cells, even in the absence of DCs 15 . Blocking retinoic acid receptors of the rAr family significantly decreased the induction of α 4 β 7 -integrin expression by T cells by GAlT-resident DCs, which shows that retinoic acid is essential for the gut-imprinting capacity of the DCs 15 . Consistently, GAlT-resident DCs, unlike DCs from other tissues, express rAlDH enzymes, which are essential for retinoic acid biosynthesis 15 . Together, these results indicate that retinoic acid is pivotal for the imprinting of gut-homing T cells.
Although vitamin A deficiency decreases the number of T and B cells in the small bowel lamina propria 15, 76, 83, 97 , it does not affect lymphocyte migration to the colon 97 . Analogously, GAlT-resident DCs imprint T and B cells with homing capacity for the small bowel, but they do not induce colon-homing T cells 93 . Therefore, retinoic acid is neither necessary nor sufficient to imprint colonhoming lymphocytes. The molecular signals that are responsible for lymphocyte homing to the colon and the reasons why T-cell migration to this compartment is controlled differently from homing to the small bowel are still to be determined.
regarding the migration of ASCs, it has been proposed that CCr10 might have a role in the homing of IgA + ASCs to the colon, mammary glands and probably to other mucosal compartments 73 (FIG. 4b) . However, it is currently unclear how CCr10 expression is induced by ASCs. recent reports indicate that IgA + ASCs might acquire CCr10 expression in colonic patches or in iliac lymph nodes following rectal immunization 98 and that the expression of this receptor can also be induced by 1,25(OH) 2 
Atherosclerosis
A chronic disorder of the arterial wall characterized by endothelial damage that gradually induces deposits of cholesterol, cellular debris, calcium and other substances. These deposits eventually lead to plaque formation and arterial stiffness.
Ischaemia-reperfusion injury
(IrI). Cellular damage caused by the return of blood supply to a tissue after a period of inadequate blood supply. The absence of oxygen and nutrients causes cellular damage, such that restoration of the blood flow results in inflammation. In vitro-generated tissue-tropic lymphocytes retain marked plasticity; skin-homing T cells can be converted to gut-homing T cells and vice versa if they are re-stimulated with or without GAlT-resident DCs, respectively 95, 96 . Similarly, previously activated B cells can be re-educated and acquire or lose gut-homing potential when they are restimulated with or without retinoic acid, respectively 76 . The decrease in α 4 β 7 -integrin and CCr9 expression observed in T and B cells that are activated in the absence of retinoic acid might be a default differentiation mechanism. However, it is also possible that other factors can actively contribute to the downregulation of gut-homing-receptor expression by lymphocytes. As both rAr and VDr must form heterodimers with rXr to signal, it is possible that 1,25(OH) 2 VD 3 could actively antagonize the effects of retinoic acid by competing for the same nuclear partner 18 . Consistent with this possibility, 1,25(OH) 2 VD 3 blocks the retinoic acid-induced upregulation of gut-homing receptors on human T cells 6, 99 . However, whether this retinoic acid antagonism by 1,25(OH) 2 VD 3 has a regulatory role in the imprinting of gut-homing lymphocytes in vivo remains unknown.
In addition to imprinting a gut-homing phenotype on lymphocytes, retinoic acid and GAlT-resident DCs also block the upregulation of the skin-homing receptors CCr4 and ligands for P-and E-selectin by T cells 15, 95 . Therefore, acquisition of a skin-homing phenotype might be the default pathway for T-cell activation in the absence of retinoic acid or when rAr signalling is blocked 100 . Nonetheless, as VD 3 as well as 1,25(OH) 2 VD 3 can be synthesized in the skin 101 , it is conceivable that, like retinoic acid in the gut, 1,25(OH) 2 VD 3 might have a reciprocal role in imprinting lymphocyte homing to the skin. In agreement with this possibility, it was recently shown that 1,25(OH) 2 VD 3 synergizes with Il-12 to induce the expression of skin-associated CCr10 by human T cells 6 . However, it was also shown that 1,25(OH) 2 VD 3 actually blocks the upregulation of ligands for E-selectin 6, 99 and the expression of fucosyltransferase-VII (reF. 99) , an enzyme essential for the synthesis of selectin ligands 102 . This was correlated with decreased homing of T cells to the inflamed skin in a model of contact hypersensitivity induced by oxazolone 99 . Although these data indicate that 1,25(OH) 2 VD 3 might block skin-homing, it should be noted that these experiments were carried out without Il-12 supplementation, which could potentially counteract the negative effect of 1,25(OH) 2 VD 3 on the expression of E-selectin ligands and skin-homing. It is also possible that 1,25(OH) 2 VD 3 induces CCr10 expression by T cells after they have homed to the skin to increase their retention in this tissue. In fact, because keratinocytes express the CCr10 ligand CC-chemokine ligand 27 (CCl27), it has been proposed that CCr10 upregulation might promote T-cell trafficking to and/or retention in the epidermis 6 . Finally, 1,25(OH) 2 VD 3 might also affect leukocyte migration by blocking chemokine synthesis at effector sites. For instance, 1,25(OH) 2 VD 3 decreased the expression of CCl2, CCl3, CXCl10 and subsequent monocyte infiltration in experimental autoimmune encephalomyelitis (EAE) 103 . Similarly, a 1,25(OH) 2 VD 3 analogue decreased the production of the chemokines CCl2, CCl5, CXCl10 and consequent T H 1-cell infiltration in non-obese diabetic (NOD) mice, a model of type 1 diabetes
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Effects of antioxidant vitamins on immunity
It has been known for more than 30 years that some vitamins with antioxidant properties, including vitamin A, vitamin B6 (pyridoxine), vitamin C (ascorbic acid) and particularly vitamin E, have protective effects on animal models of atherosclerosis and ischaemiareperfusion injury (IrI) [2] [3] [4] . Vitamin E collectively refers to eight related compounds (tocopherols and tocotrienols), of which α-tocopherol has the greatest bioavailability and is the best characterized 105 . Vitamin E decreases the release of reactive oxygen species by monocytes 106 and the expression of CD11b and very late antigen 4 (VlA4), thereby decreasing monocyte adhesion to the endothelium 106 . Vitamin E also blocks the release of pro-inflammatory cytokines, including Il-1, Il-6, TNF and the chemokine Il-8, by monocytes and macrophages 107, 108 . Moreover, vitamin E prevents the upregulation of the adhesion molecules vascular cell-adhesion molecule 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1) on the endothelium induced by oxidized low-density lipo protein (lDl) 109 and Il-1β 110 , as well as the upregulation of E-selectin and some chemokines 108 . reactive oxygen species activate the nuclear factor-κB (NF-κB) pathway 106 , which initiates many pro-inflammatory events. Therefore, the therapeutic antioxidant effect of these vitamins could be explained, at least in part, by their capacity to decrease NF-κB activation.
Vitamin E can also act directly on T cells by decreasing IFNγ production 111 and CD95l (also known as FASl) 112 expression, thereby helping to decrease inflammation and immune-mediated tissue damage. These effects on macrophages and T cells are believed to be important for the protective effect for vitamin E in animal models of atherosclerosis 108, 113 and IrI 114, 115 . Consistent with a potential physiological role for vitamin E in preventing atherosclerosis, hyperlipidemic mice that are deficient in α-tocopherol transfer protein, which is important for transporting α-tocopherol and for preventing its degradation, have more severe atherosclerosis 116 . It was recently shown that vitamin C prevents oxidative damage during ischaemia reperfusion in rats 117 and humans 4 . Notably, it was shown that vitamin C but not vitamin E prevented leukocyte adhesion to the microvascular endothelium in hamster models of oxidative endothelial stress induced by cigarette smoke or oxidized lDl 118, 119 . Differences in lipophilicity might potentially have an impact in the distribution and/or location of vitamins C and E and partially account for the differential effect of these vitamins. Therefore, it is possible that combined supplementation of vitamins C and E could
Rheumatoid arthritis
An immunological disorder that is characterized by symmetrical polyarthritis, often progressing to crippling deformation after years of synovitis. It is associated with systemic immune activation, with the presence of acute-phase reactants in the peripheral blood and with rheumatoid factor (immunoglobulins specific for IgG), which form immune complexes that are deposited in many tissues.
Inflammatory bowel disease
(IBD). A chronic condition of the intestine that is characterized by severe inflammation and mucosal destruction. The most common forms in humans are ulcerative colitis and Crohn's disease, which are believed to be T helper 2 (T H 2)-and T H 1-type diseases, respectively. However, interleukin-23 and T H 17 cells have also recently been shown to be involved in the pathology of IBD.
Graft-versus-host disease (GVHD). An immune response mounted against the recipient of an allograft by immunocompetent donor T cells that are derived from the graft. Typically, it is seen in the context of allogeneic bone-marrow transplantation.
offer synergistic benefits. The antioxidant and/or antiatherogenic role for other vitamins, such as vitamin B6 and vitamin K, is less well documented and somewhat controversial, with evidence both in favour 120, 121 and against 122 a protective role for these vitamins in atherosclerosis.
Finally, it should be noted that many of the encouraging results in animal models have not been consistently translated into a significant therapeutic benefit in controlled clinical trials of vitamin supplementation for the prevention of cardiovascular diseases and IrI
121
. Therefore, it remains to be determined whether antioxidant vitamins will prove to be useful for the treatment and/or prevention of these ailments in humans.
Vitamin metabolites in immunotherapy Vitamin D. Given that 1,25(OH) 2 VD 3 has a physiological protective role in dampening or limiting potentially pathogenic immune responses at the cellular level, one might predict that interfering with its effects could predispose to hypersensitivity or autoimmunity 7 . Consistent with this idea, levels of serum 1,25(OH) 2 VD 3 are often decreased in patients with type I diabetes 123 and SlE 8, 124 , and 1,25(OH) 2 VD 3 levels are inversely correlated with disease activity in patients with rheumatoid arthritis 125 .
Moreover, VD 3 deficiency accelerates intestinal inflammation in Il-10-deficient mice, which develop inflammatory bowel disease 126 . VD 3 deficiency might also predispose to type I diabetes 7, 127 . However, although children with rickets (typically caused by insufficient dietary supply of vitamin D) have a higher incidence of diabetes than VD 3 -sufficient children 7 , they are also more susceptible to infection 7, 128 , which suggests that VD 3 might also be important for protective immune responses. This effect could be partially mediated by the capacity of 1,25(OH) 2 VD 3 to increase the bactericidal capacity of macrophages 5, 23 . Given its immunomodulator y properties, 1,25(OH) 2 VD 3 or its analogues might be clinically useful for the treatment of inflammatory and auto immune diseases. Administration of 1,25(OH) 2 VD 3 or an analogue prevented proteinuria and prolonged life span in a mouse model of experimental SlE 129, 130 . In addition, 1,25(OH) 2 VD 3 prevented EAE in mice 103, 131, 132 , an effect that was dependent on Il-10 and Il-10 receptor signalling 132 . As 1,25(OH) 2 VD 3 in combination with glucocorticoids induces Il-10-producing T r 1 cells 133 , it is possible that 1,25(OH) 2 VD 3 might exert its therapeutic effect, at least in part, through the generation of T r 1 cells. However, induction of FOXP3 + T reg cells might also have an important role [35] [36] [37] . Other models of experimental autoimmunity in which 1,25(OH) 2 VD 3 has shown a therapeutic benefit include insulitis in NOD mice 127 , prostatitis 34 and rheumatoid arthritis 7, 134 . 1,25(OH) 2 VD 3 can also block cutaneous contact hypersensitivity 99 , an effect that could be mediated in part by blocking the induction of skin-homing-receptor expression by lymphocytes 99 . Consistent with its anti-inflammatory role, a 1,25(OH) 2 VD 3 analogue has been successfully used as a therapy for psoriasis 135, 136 . However, it should be pointed out that topical skin application of 1,25(OH) 2 VD 3 also has the potential to trigger allergic dermatitis by increasing T H 2 cell-mediated responses 137 .
It has been proposed that 1,25(OH) 2 VD 3 could also be used as an adjuvant in immunomodulatory therapy in transplantation. 1,25(OH) 2 VD 3 and a 1,25(OH) 2 VD 3 analogue prolonged the survival of mouse cardiac allografts 138, 139 , and decreased the rates of allograft rejection and increased survival in a rat model of liver transplantation 140 and in fully mismatched mouse pancreatic islet transplants 141 . In addition, a 1,25(OH) 2 VD 3 analogue provided significant protection from graft-versushost disease (GVHD) in rats 142 . Moreover, 1,25(OH) 2 VD 3 and a 1,25(OH) 2 VD 3 analogue significantly prevented chronic allograft rejection in a rat model of renal transplantation 143 and delayed chronic allograft rejection in a mouse model of aortic transplantation 139 . Interestingly, polymorphisms in VDr are associated with a higher incidence of GVHD in patients who undergo bone-marrow transplantation 144 , which indicates that 1,25(OH) 2 56, 88, 89 and increased mortality associated with gastrointestinal and respiratory infections 150 . Conversely, vitamin A supplementation correlates with a significant decrease in diarrhoea and mortality in HIV-infected or malnourished children 76, 151, 152 . Therefore, retinoic acid or rAr agonists could be used for targeting T-and B-cell responses to the gut mucosa for vaccination purposes.
In addition, given that retinoic acid can potentiate the TGFβ-mediated induction of T reg cells while antagonizing the differentiation of pro-inflammatory T H 17 cells 64 , treatment with retinoic acid together with TGFβ could be a useful strategy to generate T reg cells for treating inflammatory pathologies affecting not only the intestine, but also peripheral tissues. In fact, retinoic acid and rAragonists have been successfully used in some models of autoimmune inflammation, such as EAE 153, 154 , adjuvant arthritis 155, 156 and experimental nephritis 157 . retinoids have also been successfully used to treat psoriasis 158 and they are effective in treating and/or preventing contact dermatitis in mice and humans 159, 160 . In these models, therapeutic effects partially correlated with the induction of T H 2-cell responses 153 and decreased expression of α 4 β 1 -integrin on effector T cells 157 , but the role of retinoic acid in the induction of T reg cells and the inhibition of T H 17 cells in these settings has yet to be assessed. 6, 39 while blocking the expression of skin-and gut-homing receptors 6, 99 . However, the in vivo relevance of the effects of 1,25(OH) 2 VD 3 on CCr10 expression by T cells that are infiltrating the skin and by IgA + ASCs that are migrating to the gut lamina propria remains to be determined. In addition, although GAlT-resident DCs enhance IgA secretion and induce gut-homing effector lymphocytes ex vivo, it will be important to determine the relative in vivo contribution of DCs versus other potential sources of retinoic acid in the gut (such as IECs), and to determine whether there are retinoic acid-independent mechanisms of imprinting a gut-homing phenotype. Moreover, as GAlT-resident DCs can also enhance the differentiation of TGFβ-induced T reg cells, it will be necessary to determine the in vivo scenarios in which GAlT-resident DCs and retinoic acid promote either effector or suppressive T-cell responses. Along these same lines, it will be important to study the contribution of these in situ-generated gut T reg cells compared with their systemic counterparts in maintaining immune tolerance at intestinal and extra-intestinal sites.
Concluding remarks
Aside from the antioxidant effects of vitamins C and E that have been demonstrated in animal models of cardiovascular disease and IrI, there is a lack of published information on the impact of these and other vitamins, such as vitamin B6 and K [120] [121] [122] , on the adaptive immune system and in other inflammatory settings, such as autoimmune diseases. whether these vitamins will offer a therapeutic benefit in the settings of human cardiovascular diseases, IrI and other pathologies remains unclear.
Although many open questions remain, there is promise that vitamin A and D metabolites or their analogues have the potential to be used in clinical settings for therapeutic benefit. In particular, it will be important to assess the impact of using 1,25(OH) 2 VD 3 analogues as an adjuvant immunomodulatory therapy in the setting of autoimmune diseases and in transplant recipients. It will also be important to determine the net effects of retinoic acid or synthetic rAr-agonists, especially in the intestine, where these agents appear to have a role in enhancing immune responses. The capacity of vitamin A metabolites to foster gut-homing T cells might improve strategies of mucosal vaccination or aid in decreasing pathogenic immunity by potentiating the induction of T reg cells. This paper reports for the first time that retinoic acid is necessary and sufficient to induce gut-homing receptors on T cells. It is also shown that gut-associated DCs can metabolize dietary vitamin A into retinoic acid, which explains their capacity to imprint gut-homing lymphocytes. 
